×
Please click
here
if you are not redirected within a few seconds.
All
News
Videos
Images
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc ...
KLAS 8 News Now
NEW YORK, NY / ACCESSWIRE / November 7, 2023 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the...
14 hours ago
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
Yahoo Movies Canada
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $36.44, moving -0.87% from the previous trading session.
2 days ago
Quest Partners LLC Takes $118000 Position in Cassava Sciences, Inc. (NASDAQ:SAVA)
Defense World
Read Quest Partners LLC Takes $118000 Position in Cassava Sciences, Inc. (NASDAQ:SAVA) at Defense World.
4 days ago
Is There Any Hope for Cassava Sciences Stock?
The Motley Fool
Key Points. Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to...
3 months ago
Cassava Sciences' Alzheimer's clinical trials should be halted
STAT
It's time for the FDA to halt Cassava Sciences' Alzheimer's clinical trials ... The Food and Drug Administration should halt Cassava Sciences'...
7 months ago
Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go? (NASDAQ:SAVA)
Seeking Alpha
Cassava Sciences: A 3.2 improvement in mild to moderate Alzheimer's disease at one year. Actual: 2.45 point decline in mild to moderate...
2 months ago
Co-developer of Cassava's potential Alzheimer's drug cited for 'egregious misconduct'
Science | AAAS
Cassava Sciences, a biotech company whose work on the experimental Alzheimer's drug simufilam has been heavily criticized and is the subject...
7 months ago
Insider Stock Buying Reaches US$831.4k On Cassava Sciences
Simply Wall Street
In the last year, multiple insiders have substantially increased their holdings of Cassava Sciences, Inc. ( NASDAQ:SAVA...
3 weeks ago
Plagued By Controversy, Promising Alzheimer's Treatment, 2024 To Be Pivotal For Cassava Sciences
In Vivo
All eyes will be on Cassava Sciences in 2024, as it completes two Phase III trials of its closely watched Alzheimer's disease candidate, simufilam.
1 month ago
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
GlobeNewswire
Million In Total Gross Proceeds from Warrant Distribution.Over 1900 Patients with Alzheimer's Disease Are Randomized in Phase 3 Trials of...
3 weeks ago